

AMENDMENTS TO THE CLAIMS

1-51. (Cancelled)

52. (Previously Presented) A composition for activating a non-specific immune response in a subject comprising:

an oligonucleotide delivery complex, wherein the oligonucleotide delivery complex contains an immunostimulatory CpG containing oligonucleotide associated with a lipid or a sterol, wherein the lipid is a cationic lipid, virosome or liposome,

wherein the composition activates a systemic, non-specific immune response in the subject.

53. (Previously Presented) The composition of claim 52, wherein the non-specific immune response comprises stimulating natural killer (NK) cell activity.

54. (Currently Amended) The composition of claim 52, wherein the CpG is not part of a 6 base palindromic sequence.

55. (Previously Presented) The composition of claim 52, wherein the CpG includes a phosphate backbone modification.

56. (Previously Presented) The composition of claim 55, wherein the phosphate backbone is a phosphorothioate backbone modification.

57. (Withdrawn) The composition of claim 52, wherein the sterol is cholesterol.

58. (Previously Presented) The composition of claim 52, wherein the oligonucleotide is 8-100 nucleotides in length.

59. (Previously Presented) The composition of claim 58, wherein the oligonucleotide is 8-40 nucleotides in length.

60. (Currently Amended) The composition of claim 52, wherein the oligonucleotide comprises the formula



wherein C and G are unmethylated, X_1 , X_2 , X_3 and X_4 are nucleotides and a GCG trinucleotide sequence is not present at or near the 5' or 3' termini.

61. (Previously Presented) The composition of claim 52, further comprising a pharmaceutically acceptable carrier.

62. (Previously Presented) The composition of claim 52, wherein the oligonucleotide is encapsulated in the cationic liposome.

63. (Previously Presented) The composition of claim 52, wherein the oligonucleotide is synthetic.

64. (Currently Amended) The composition of claim 52, wherein the composition ~~activates a non-specific immune response when administered~~ is formulated for administration by an intravenous or intraperitoneal route.

65. (Withdrawn) A method for activating a non-specific immune response in a subject comprising:

administering to a subject a composition comprising an oligonucleotide delivery complex, wherein the oligonucleotide delivery complex contains an immunostimulatory CpG containing oligonucleotide associated with a lipid or a sterol, wherein the lipid is a cationic lipid, virosome or liposome.

66. (Withdrawn) The method of claim 65, wherein the non-specific immune response comprises stimulating natural killer (NK) cell activity.

67. (Withdrawn) The method of claim 65, wherein the CpG is not part of a palindromic sequence.

68. (Withdrawn) The method of claim 65, wherein the CpG includes a phosphate backbone modification.

69. (Withdrawn) The method of claim 68, wherein the phosphate backbone is a phosphorothioate backbone modification.

70. (Withdrawn) The method of claim 65, wherein the sterol is cholesterol.

71. (Withdrawn) The method of claim 65, wherein the oligonucleotide is 8-100 nucleotides in length.

72. (Withdrawn) The method of claim 71, wherein the oligonucleotide is 8-40 nucleotides in length.

73. (Withdrawn) The method of claim 65, wherein the oligonucleotide comprises the formula



wherein C and G are unmethylated, X_1 , X_2 , X_3 and X_4 are nucleotides and a GCG trinucleotide sequence is not present at or near the 5' or 3' termini.

74. (Withdrawn) The method of claim 65, further comprising a pharmaceutically acceptable carrier.

75. (Withdrawn) The method of claim 65, wherein the oligonucleotide is encapsulated in the cationic liposome.

76. (Withdrawn) The method of claim 65, wherein the oligonucleotide is synthetic.

77. (Withdrawn) The method of claim 65, wherein the composition activates a non-specific immune response when administered by an intravenous or intraperitoneal route.